Our patient advocacy team was proud to participate in the Alzheimer's Foundation of America’s Educating America Tour stop in Albuquerque, NM! We are honored to support this initiative which connects communities across the country with information about #Alzheimers disease, #brainhealth, caregiving and more. Thank you to the AFA team for your continued efforts in supporting the Alzheimer’s community.
Alector
生物技术研究
South San Francisco，California 18,764 位关注者
We are on a mission to make brain disorders history.
关于我们
We are a late-stage clinical biotechnology company with a mission to make degenerative brain disorders history. Our robust portfolio of therapies is focused on counteracting the devastating progression of neurodegenerative diseases, particularly in areas of high unmet need where therapeutic options are limited. We are at the forefront of a scientific and clinical revolution, committed to understanding the complex mechanisms that drive neurodegenerative diseases, including the roles of toxic misfolded proteins, deficient proteins, and lysosomal, immune system, and neuronal dysfunction. We aim to develop product candidates that remove toxic proteins, replace critical deficient proteins, and restore immune and nerve cells to normal function. To pursue this aim, we are advancing a portfolio of programs that address genetically validated targets. These programs leverage our deep understanding of the genetic underpinnings of these diseases, combined with our expertise in drug development, proprietary protein engineering, antibody discovery, and our innovative Alector Brain Carrier (ABC) technology for blood-brain barrier (BBB) transport.?We are advancing ABC, our proprietary, versatile BBB technology platform and selectively applying it within our portfolio. Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.
- 网站
-
https://alector.com
Alector的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，California
- 类型
- 上市公司
- 创立
- 2013
- 领域
- Biotechnology、Neurodegenerative disease和Neurodegeneration
地点
-
主要
获取路线
131 Oyster Point Blvd
Suite 600
US，California，South San Francisco，94080
Alector员工
动态
-
#DYK that an estimated 50 million people worldwide are living with a #neurodegenerativedisease? This #BrainAwarenessWeek, Alector invites everyone to champion #brainhealth while we work to slow the progression of neurodegenerative diseases.
-
-
This Saturday is International Women’s Day 2025. In celebration, we want to acknowledge the accomplished?women at Alector. We are committed to taking action to create equal opportunities and inclusive spaces for women, and everyone on the team.? #AccelerateAction #IWD2025
-
-
Alector was thrilled to welcome Linde Jacobs, featured in The New York Times for her inspiring advocacy work on behalf of #FTD as a guest speaker during our 2nd-annual Collaboration Week. Her keen insights inspired and motivated our team to continue driving our mission forward in 2025.?
-
-
Today, we recognize #RareDiseaseDay. #DYK 1 in 10 Americans are impacted by a rare disease, including conditions such as #frontotemporaldementia? We are proud to be part of the community working towards developing treatment options for people living with rare conditions such as #FTD. Learn more about Rare Disease Day and how you can get involved here: https://bit.ly/4284MlQ
-
-
Today, we reported fourth quarter and full year 2024 financial results and recent portfolio and business updates. Join us for a conference call with members of our management team today at 4:30 pm ET. Read the full release: https://bit.ly/4hVV8HR #investors #biotech
-
-
Alector is proud to sponsor the UPENN Virtual 2025 FTDC Familial Conference: Uncovering the Genetics of FTD/ALS. This event addresses the unique challenges of familial and genetic forms of these conditions, offering insights from genetic counselors, neurologists, and social workers. To learn more and register, visit https://bit.ly/41uxe0r
-
-
We are excited to announce that our management team will be participating in the following March investor conferences. To learn more, visit https://bit.ly/41v5g4z
-
-
Our team is grateful for the opportunity to visit The Association for Frontotemporal Degeneration (AFTD) HQ and connect with the incredible team supporting those impacted by #FTD. Together, we’re working toward greater understanding and care for families and individuals affected by this complex disease.?
-
-
On Wednesday, February 26, 2025 at 4:30 p.m. ET, we will host a conference call and webcast to discuss results for the fourth quarter ended December 31, 2024, and provide a full-year business update. Learn more: https://bit.ly/419xv7w #biotech #investors
-